Editas Medicine Announces Chief Financial Officer Transition
Editas Medicine (Nasdaq: EDIT) announced a leadership transition as Chief Financial Officer Erick J. Lucera will step down effective March 28, 2025, to pursue an external opportunity. Amy Parison, current Senior Vice President of Finance, has been appointed as the new CFO.
Parison brings over 18 years of financial, accounting, and business development experience in life sciences to the role. During her two-and-a-half-year tenure at Editas, she has been instrumental in equity financings, licensing transactions, and royalty monetization. Her previous experience includes positions at Rubius Therapeutics as Corporate Controller and various roles at Vertex Pharmaceuticals.
CEO Gilmore O'Neill praised Parison's financial decision-making, accounting acumen, and team leadership abilities, while acknowledging Lucera's contributions in positioning Editas financially and developing talent.
Editas Medicine (Nasdaq: EDIT) ha annunciato un cambiamento nella leadership poiché il Chief Financial Officer Erick J. Lucera si dimetterà con effetto dal 28 marzo 2025 per perseguire un'opportunità esterna. Amy Parison, attuale Vicepresidente Senior della Finanza, è stata nominata nuovo CFO.
Parison porta con sé oltre 18 anni di esperienza in finanza, contabilità e sviluppo commerciale nel settore delle scienze della vita. Durante il suo mandato di due anni e mezzo in Editas, è stata fondamentale in finanziamenti azionari, transazioni di licenza e monetizzazione delle royalties. Le sue precedenti esperienze includono ruoli come Corporate Controller presso Rubius Therapeutics e varie posizioni presso Vertex Pharmaceuticals.
Il CEO Gilmore O'Neill ha elogiato la capacità di decisione finanziaria di Parison, la sua competenza contabile e le sue abilità di leadership, riconoscendo al contempo i contributi di Lucera nel posizionare Editas finanziariamente e nello sviluppo dei talenti.
Editas Medicine (Nasdaq: EDIT) anunció una transición en el liderazgo, ya que el Director Financiero Erick J. Lucera dejará su puesto a partir del 28 de marzo de 2025 para buscar una oportunidad externa. Amy Parison, actual Vicepresidenta Senior de Finanzas, ha sido nombrada nueva CFO.
Parison aporta más de 18 años de experiencia en finanzas, contabilidad y desarrollo empresarial en ciencias de la vida. Durante su mandato de dos años y medio en Editas, ha sido fundamental en financiamientos de capital, transacciones de licencias y monetización de regalías. Su experiencia previa incluye puestos en Rubius Therapeutics como Controladora Corporativa y varios roles en Vertex Pharmaceuticals.
El CEO Gilmore O'Neill elogió la toma de decisiones financieras de Parison, su agudeza contable y sus habilidades de liderazgo, reconociendo al mismo tiempo las contribuciones de Lucera en el posicionamiento financiero de Editas y en el desarrollo de talento.
Editas Medicine (Nasdaq: EDIT)는 최고 재무 책임자(Chief Financial Officer)인 Erick J. Lucera가 2025년 3월 28일부로 사임하고 외부 기회를 추구할 것이라고 발표했습니다. Amy Parison은 현재 재무 부사장(Senior Vice President of Finance)으로 새 CFO로 임명되었습니다.
Parison은 생명과학 분야에서 18년 이상의 재무, 회계 및 사업 개발 경험을 가지고 있습니다. Editas에서 2년 반의 재직 기간 동안 그녀는 자본 조달, 라이선스 거래 및 로열티 수익화에 중요한 역할을 했습니다. 그녀의 이전 경험으로는 Rubius Therapeutics에서 기업 회계 담당자로 일한 것과 Vertex Pharmaceuticals에서의 여러 역할이 포함됩니다.
CEO Gilmore O'Neill은 Parison의 재무 의사 결정, 회계 능력 및 팀 리더십 능력을 칭찬하며, Lucera가 Editas의 재무적 위치를 설정하고 인재를 개발하는 데 기여한 점을 인정했습니다.
Editas Medicine (Nasdaq: EDIT) a annoncé une transition de leadership, le directeur financier Erick J. Lucera démissionnant à compter du 28 mars 2025 pour poursuivre une opportunité externe. Amy Parison, actuelle vice-présidente senior des finances, a été nommée nouvelle CFO.
Parison apporte plus de 18 ans d'expérience en finance, comptabilité et développement commercial dans le domaine des sciences de la vie. Au cours de son mandat de deux ans et demi chez Editas, elle a joué un rôle essentiel dans les financements par actions, les transactions de licences et la monétisation des redevances. Son expérience précédente comprend des postes chez Rubius Therapeutics en tant que contrôleur d'entreprise et divers rôles chez Vertex Pharmaceuticals.
Le PDG Gilmore O'Neill a loué la prise de décision financière de Parison, son expertise comptable et ses capacités de leadership d'équipe, tout en reconnaissant les contributions de Lucera au positionnement financier d'Editas et au développement des talents.
Editas Medicine (Nasdaq: EDIT) hat einen Führungswechsel angekündigt, da der Chief Financial Officer Erick J. Lucera zum 28. März 2025 zurücktritt, um eine externe Möglichkeit zu verfolgen. Amy Parison, derzeitige Senior Vice President of Finance, wurde zur neuen CFO ernannt.
Parison bringt über 18 Jahre Erfahrung in Finanzen, Rechnungswesen und Geschäftsentwicklung im Bereich der Lebenswissenschaften mit. Während ihrer zweieinhalbjährigen Amtszeit bei Editas war sie maßgeblich an Eigenkapitalfinanzierungen, Lizenztransaktionen und der Monetarisierung von Lizenzgebühren beteiligt. Zu ihren früheren Erfahrungen gehören Positionen als Corporate Controller bei Rubius Therapeutics und verschiedene Rollen bei Vertex Pharmaceuticals.
CEO Gilmore O'Neill lobte Parisons finanzielle Entscheidungsfindung, ihre Buchhaltungsfähigkeiten und ihre Teamführungsfähigkeiten und erkannte gleichzeitig Luceras Beiträge zur finanziellen Positionierung von Editas und zur Talententwicklung an.
- Seamless internal succession plan with experienced finance executive
- New CFO brings 18+ years of relevant industry experience
- Demonstrated track record in equity financing and licensing transactions
- Departure of key executive officer could create temporary transition risks
Erick J. Lucera to Step Down as CFO to pursue another opportunity
Senior Vice President of Finance Amy Parison Appointed CFO
CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer.
“We are thrilled to promote Amy to the executive leadership team as our new CFO. Amy joined Editas two and a half years ago as our head of Finance, working closely with the CFO. Her track record of financial decision-making, accounting acumen, and team leadership abilities make her the natural choice to succeed Erick as Editas’ CFO,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer.
Dr. O’Neill continued, “On behalf of the entire company, I would like to thank Erick for his contributions to Editas, including positioning Editas financially to ensure our ability to meet our goals, and his dedication to talent development. Under his leadership, Amy honed the financial and leadership skills necessary to best position Editas for success as we pursue our goal of delivering life-changing medicines to patients with previously untreatable or undertreated diseases. We wish him the best of luck in his new venture.”
“I am honored and excited for the opportunity to transition to CFO at this pivotal time for Editas, as a fully in vivo gene editing company. I am confident I can leverage my prior experience and my deep knowledge of Editas to continue our focus on developing innovative in vivo medicines for people living with serious diseases while driving shareholder value. I look forward to working with Gilmore, the board of directors, and the entire team at Editas Medicine in my new role,” said Amy Parison, Senior Vice President and Chief Financial Officer, Editas Medicine.
Mr. Lucera added, “Being a part of Editas Medicine’s journey, helping transition the company towards its goal, and working to bring in capital to support that vision has been an honor. And, as a big believer in developing the team, I look forward to seeing Amy continue to grow and have success as Editas’ new CFO.”
Ms. Parison has more than 18 years of financial, accounting, and business development experience in life sciences. During her time at Editas, she has served in multiple roles of increasing responsibilities including Senior Vice President, Finance, and Vice President and Corporate Controller. In partnership with the ELT, she worked on equity financings, licensing transactions and royalty monetization. Prior to Editas, Ms. Parison served as Corporate Controller of Rubius Therapeutics where she led the accounting team following the Company’s IPO, building critical business and financial processes. Prior to Rubius, she was at Vertex Pharmaceuticals, where she held several roles of increasing responsibility within the accounting and finance teams and supported forecasting, budgeting, and business development. She started her career with PricewaterhouseCoopers, LLP. Ms. Parison holds a BS and a Master of Accounting, both from Babson College.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a363292-5cf0-46ce-a4ba-5efcc89740a6
Media and Investor Contact: ir@editasmed.com
FAQ
When will Erick Lucera step down as CFO of Editas Medicine (EDIT)?
Who is replacing Erick Lucera as the new CFO at Editas Medicine (EDIT)?
What is Amy Parison's experience before joining Editas Medicine (EDIT)?
What key achievements did Amy Parison accomplish at Editas Medicine (EDIT)?
